Velpanat Tablet (28’s) is a potent antiviral medication primarily used for the treatment of chronic hepatitis C virus (HCV) infection. This combination drug contains two active ingredients: Sofosbuvir, which is a nucleotide analog polymerase inhibitor, and Velpatasvir, a pan-genotypic NS5A inhibitor. Together, these components work synergistically to inhibit the replication of the hepatitis C virus, leading to a significant reduction in viral load and, ultimately, the potential for a sustained virologic response. Velpanat is designed for oral administration and is typically prescribed for a treatment duration of 12 weeks, depending on the specific genotype of the virus and the patient’s medical history. The formulation is well-tolerated and has been shown to be effective across various patient populations, including those with liver cirrhosis. With its dual-action mechanism, Velpanat Tablet represents a significant advancement in the management of hepatitis C, offering hope for patients seeking a cure.